Renovaro signs binding LOI to buy Predictive Oncology; preferred stock valued at $3/share

Lunai Bioworks Inc.

POAI shareholders to receive new Renovaro preferred stock in 1:1 exchange; preferred stock redeemable at $3.00 per share after 18 months.
Deal conditions include minimum $15M fundraising by Renovaro and POAI shareholder approval; definitive agreement due by Feb 28, 2025.
If POAI warrants not exercised by Jan 15, Renovaro will buy up to 2.33M POAI common shares at $1.07 each.
Transaction provides access to POAI's biobank of 150,000 tumor specimens and AI platform with 92% drug-response accuracy.
Combined entity aims to launch decision-support platform for oncologists in 2025, integrating multi-omic diagnostics and drug discovery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.